Articles tagged "Kidney transplantation"

2016 American Transplant Congress
De Novo Proliferative Glomerulonephritis with Monoclonal IgG Deposits of the IgG1κ Subtype in a Kidney Allograft: Protocol Biopsy Findings.
T. Tsuji,¹ M. Miura,² M. Yanai,¹ H. Itami,¹ Y. Ishii,¹ M. Akimoto,¹ Y. Fukasawa.¹
¹Department of Pathology, Sapporo City General Hospital, Sapporo, Japan; ²Departments of Renal Transplant Surgery and Urology, Sapporo Hokuyu Hospital, Sapporo, Japan.
Proliferative glomerulonephritis with monoclonal immunoglobulin G (IgG) deposits (PGNMID) has recently been described in cases with glomerular disease. Only a dozen cases of recurrent or…
2016 American Transplant Congress
Urinary Virome in Human Kidney Transplants Reveals Multiple Virus Subtypes with Distinct Genome Polymorphisms.
R. Ranjan,¹ A. Rani,¹ H. McGee,¹ D. Brennan,² P. Finn,¹ D. Perkins.^1,3
¹Medicine, University of Illinois, Chicago, IL; ²Division of Renal Diseases, Washington University School of Medicine, St. Louis, MO; ³Surgery, University of Illinois, Chicago, IL.
Recent studies have established that human urine has its own unique microbiome, but little is known about the virome. The human virome is the collection…
2016 American Transplant Congress
Concomitant Proton Pump Inhibitor and Mycophenolate Mofetil Use in Renal Transplant Recipients.
K. Patel,¹ B. Stephany,² J. Barnes,¹ S. Bauer,¹ M. Spinner.¹
¹Department of Pharmacy, Cleveland Clinic, Cleveland, OH; ²Department of Nephrology and Hypertension, Cleveland Clinic, Cleveland, OH.
Pharmacokinetic (PK) data show reduced mycophenolic acid levels in transplant recipients taking mycophenolate mofetil (MMF) and proton pump inhibitors (PPIs) concomitantly. MMF dosing is not…
2016 American Transplant Congress
Pulse Wave Velocity Amongst African-American Kidney Transplant Recipients Randomized to Once-Daily MeltDose Tacrolimus Tablets (Envarsus XR) vs. Traditional Twice-Daily Tacrolimus Capsules: Exploratory Results from a Phase III Trial.
J. Trofe-Clark,^1,2 R. Townsend,² R. Neubauer,² M. Lim,² L. Callahan,³ R. Bloom.²
¹Pharmacy Services, Hospital of the University of Pennsylvania, Philadelphia, PA; ²Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; ³Veloxis Pharmaceuticals, Edison, NJ.
Cardiovascular (CV) death is a leading cause of death in kidney transplant recipients (KTR). Increased aortic arterial stiffness is strongly associated with the development of…
2016 American Transplant Congress
HLA Class II and BK Virus Reactivation in Renal Transplant Recipients.
P. Shah,¹ K. Anderson,² M. Aubrey,² C. Roark,² B. Freed,² A. Wiseman.¹
¹Division of Renal Diseases and Hypertension, University of Colorado School of Medicine, Aurora, CO; ²Division of Immunology, University of Colorado School of Medicine, Aurora, CO.
BK Viremia (BKV) and subsequent BK nephropathy are associated with renal graft loss. The Human Leukocyte Antigen (HLA) region has been implicated in susceptibility to…
2016 American Transplant Congress
Variation in Co-Medication Use According to Kidney Transplant Immunosuppressive Regimen: Application of Integrated Registry and Pharmacy Claims Data.
K. Lentine,¹ A. Naik,² M. Schnitzler,¹ D. Axelrod,³ J. Chen,¹ D. Brennan,⁴ D. Segev,⁵ B. Kasiske,⁶ H. Randall,¹ V. Dharnidharka.⁴
¹Saint Louis Univ, St. Louis; ²Univ Michigan, Detroit; ³Dartmouth Univ, Hanover; ⁴Washington Univ, St. Louis; ⁵Johns Hopkins Univ, Baltimore; ⁶Univ Minnesota, Minneapolis.
Background: While modern immunosuppressive therapies (ISx) have substantially reduced acute rejection, ISx medications have many side effects, and transplant recipients must take an array of…
2016 American Transplant Congress
Sociodemographic and Comorbidity Differences Between Dialysis, Waitlisted and Transplant Patients in the UK: Findings from the ATTOM Study.
D. Wu,¹ M. Robb,² C. Watson,³ R. Ravanan,⁴ J. Forsythe,¹ A. Bradley,³ G. Oniscu.¹
¹Royal Infirmary of Edinburgh, Edinburgh, United Kingdom; ²NHSBT, Bristol, United Kingdom; ³University of Cambridge, Cambridge, United Kingdom; ⁴Southmead Hospital, Bristol, United Kingdom.
IntroductionAccess to Transplantation and Transplant Outcome Measures (ATTOM) is a prospective cohort study involving all 72 UK renal units, investigating factors affecting access to and…
2016 American Transplant Congress
The Presence of CMV-Specific T-Cells in CMV-Seronegative Kidney Transplant Recipients Predicts Outcome After Kidney Transplantation.
T. Schachtner,^1,2 M. Stein,² P. Reinke.^1,2
¹Nephrology and Internal Intensive Care, Charite Campus Virchow Clinic, Berlin, Germany; ²Berlin-Brandenburg Center for Regenerative Therapies, Charite Campus Virchow Clinic, Berlin, Germany.
CMV-seronegative kidney transplant recipients (KTRs) from CMV-seropositive donors are at highly increased risk of primary CMV-infection with associated inferior outcomes after kidney transplantation. Presence of…
2016 American Transplant Congress
Graft Outcomes in Pediatric Kidney Transplants Are Better with Laparoscopic Donor Nephrectomy and High Volume Centers.
J. Burg,¹ D. Scott,¹ K. Roayaie,¹ E. Maynard,¹ J. Barry,² C. Enestvedt.¹
¹Abdominal Organ Transplantation, OHSU, Portland, OR; ²Urology, OHSU, Portland, OR.
Purpose Initial reports for pediatric kidney recipients suggested superior outcomes for open donor (ODN) compared to laparoscopic donor nephrectomy (LDN). Current outcomes based on donor…
2016 American Transplant Congress
Long-Term Outcomes of ATG versus IL-2 Receptor Antagonist in Low Risk Kidney Transplant Recipients: Donor Factors.
F. Al Ammary, S. Bae, A. Massie, N. Desai, N. Dagher, E. Kraus, A. Wiseman, D. Segev.
JHU, Baltimore; CU, Denver.
Controversy exists regarding the optimal choice of induction therapy in low-risk kidney transplant (KT) recipients. Current guidelines specify induction choices in KT based on recipient…